Pet Vaccines

Global Pet Vaccines Market to Reach US$9.5 Billion by 2030

The global market for Pet Vaccines estimated at US$7.1 Billion in the year 2024, is expected to reach US$9.5 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2024-2030. Dogs, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$5.0 Billion by the end of the analysis period. Growth in the Cats segment is estimated at 3.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.9 Billion While China is Forecast to Grow at 9.0% CAGR

The Pet Vaccines market in the U.S. is estimated at US$1.9 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 9.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 3.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Pet Vaccines Market – Key Trends & Drivers Summarized

Why Are Pet Vaccines Critical in the Era of Zoonotic Risk Awareness and Preventive Veterinary Care?

Pet vaccines are experiencing rising demand globally as pet owners, veterinarians, and public health authorities place stronger emphasis on disease prevention, longevity, and zoonotic risk mitigation. Vaccines form the frontline defense against contagious and potentially fatal diseases such as rabies, distemper, parvovirus, feline leukemia, and kennel cough. With increased urbanization and closer human-pet cohabitation, immunization is no longer just a veterinary recommendation—it’s a regulatory and ethical imperative in companion animal care.

The COVID-19 pandemic has elevated awareness of interspecies disease transmission, pushing both governments and individuals to adhere more strictly to vaccination schedules. In many jurisdictions, rabies vaccination is mandatory, while others require proof of immunization for boarding, travel, and adoption. These regulations, along with broader efforts to professionalize pet healthcare, are reinforcing the role of core and non-core vaccines as standard components of wellness protocols across cats, dogs, and exotic companion animals.

How Are Innovations in Delivery Methods, Formulations, and Combination Vaccines Enhancing Compliance?

Technological advances in vaccine formulation and delivery are improving efficacy, reducing side effects, and enhancing compliance among pet owners and veterinarians. Modified-live virus (MLV) and recombinant vaccines now offer broader immune protection with fewer adverse reactions. Intranasal and transdermal delivery systems are also being developed to minimize injection site discomfort and stress, particularly in cats and small-breed dogs.

Combination vaccines, such as DAPP (Distemper, Adenovirus, Parainfluenza, Parvovirus) or FVRCP (Feline Viral Rhinotracheitis, Calicivirus, Panleukopenia), are gaining wide acceptance for their convenience and broad-spectrum protection. These formulations reduce the number of veterinary visits and injections required, improving owner adherence and animal welfare. Additionally, manufacturers are investing in adjuvant technologies that enhance immune response while minimizing inflammation or allergic reactions, especially in pets with chronic health conditions or advanced age.

Why Are Companion Animal Healthcare Ecosystems and Emerging Market Dynamics Driving Access and Uptake?

The rise of organized veterinary care networks, mobile vaccination clinics, pet insurance coverage, and smart scheduling apps is enabling wider access to pet vaccines. Wellness plans bundled with annual check-ups are now common in North America and Europe, encouraging consistent immunization. Meanwhile, in emerging economies such as India, Brazil, and Southeast Asia, rising incomes and urban pet adoption are triggering demand for affordable, government-supported immunization programs.

Non-governmental organizations (NGOs), international animal welfare agencies, and public health authorities are also playing a pivotal role in extending vaccination coverage in underserved areas. Mass rabies vaccination campaigns, street dog immunization drives, and educational initiatives are creating scalable models for community-wide disease prevention. Veterinary telemedicine, doorstep services, and e-pharmacy platforms are making vaccine access more streamlined and less intimidating for pet owners.

What’s Fueling the Global Expansion of the Pet Vaccines Market?

The growth in the pet vaccines market is driven by several factors including the increasing global pet population, heightened awareness of zoonotic diseases, and the proliferation of organized pet healthcare frameworks. A major growth driver is the integration of preventive care into standard veterinary services and consumer expectations—shifting the focus from reactive treatment to proactive disease management.

Advancements in vaccine technology, expansion of veterinary infrastructure, and public-private initiatives in both developed and developing markets are creating a robust demand environment. With the convergence of regulatory support, digital healthcare integration, and consumer-driven spending on pet wellness, the pet vaccines market is positioned for sustained global growth. As immunization becomes central to responsible pet parenting and population health strategy, vaccines will remain the cornerstone of preventive veterinary medicine.

SCOPE OF STUDY:

The report analyzes the Pet Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Application (Dogs, Cats, Rabbits, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Bayer AG
• Bimeda Biologicals
• Boehringer Ingelheim
• Calier
• Ceva Santé Animale
• China Animal Husbandry Industry Co., Ltd.
• Dechra Pharmaceuticals PLC
• Elanco Animal Health
• Hester Biosciences Limited
• HIPRA
• Intervet (MSD Animal Health)
• Neogen Corporation
• Phibro Animal Health Corporation
• Sanofi
• Tianjin Ringpu Biotechnology Co., Ltd.
• Vaxxinova
• Veterquimica
• Vetoquinol
• Virbac
• Zoetis Inc.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more